These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 16906777)

  • 41. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Pharmacological consequences of the targeting of epidermal growth factor receptor].
    Milano G; Magné N
    Bull Cancer; 2003 Nov; 90 Spec No():S197-201. PubMed ID: 14763140
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer.
    Meyerhardt JA; Heseltine D; Ogino S; Clark JW; Enzinger PC; Ryan DP; Earle CC; Zhu AX; Fuchs CS
    Clin Colorectal Cancer; 2006 May; 6(1):59-65. PubMed ID: 16796793
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
    Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
    [TBL] [Abstract][Full Text] [Related]  

  • 45. EGFR-targeted therapies in colorectal cancer.
    Overman MJ; Hoff PM
    Dis Colon Rectum; 2007 Aug; 50(8):1259-70. PubMed ID: 17566832
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer.
    Van Cutsem E
    Oncologist; 2006 Oct; 11(9):1010-7. PubMed ID: 17030643
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer.
    Dienstmann R; Salazar R; Tabernero J
    Am Soc Clin Oncol Educ Book; 2015; ():e149-56. PubMed ID: 25993166
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
    Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
    Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.
    Okada Y; Miyamoto H; Goji T; Takayama T
    Digestion; 2014; 89(1):18-23. PubMed ID: 24458108
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
    Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
    Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New directions for ZD1839 in the treatment of solid tumors.
    Schiller JH
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):49-55. PubMed ID: 12644984
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting epidermal growth factor receptor--are we missing the mark?
    Dancey JE; Freidlin B
    Lancet; 2003 Jul; 362(9377):62-4. PubMed ID: 12853203
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment paradigms with epidermal growth factor receptor-targeted therapies in colorectal cancer.
    Stein S; Cohen DJ; Hochster HS
    Clin Colorectal Cancer; 2010 Jun; 9 Suppl 1():S44-50. PubMed ID: 20630850
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epidermal Growth Factor Receptor (EGFR) Inhibitors and Cancer Therapeutics. Proceedings of the Radiation Therapy Oncology Group Symposium. Philadelphia, Pennsylvania, USA. June 14, 2002.
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):898-1007. PubMed ID: 14967448
    [No Abstract]   [Full Text] [Related]  

  • 55. Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer.
    Mirone G; Shukla A; Marfe G
    Crit Rev Oncol Hematol; 2016 Jan; 97():85-95. PubMed ID: 26364891
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-epidermal growth factor receptor strategies to enhance radiation action.
    Lammering G
    Curr Med Chem Anticancer Agents; 2003 Sep; 3(5):327-33. PubMed ID: 12871078
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epidermal growth factor receptor expression and gene copy number analysis in gastric carcinoma samples from Chinese patients.
    Zhang F; Yang X; Li L; Sun L; Wang BO; Yu X
    Oncol Lett; 2016 Jan; 11(1):173-181. PubMed ID: 26870185
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A matricellular protein and EGF-like repeat signalling in the social amoebozoan Dictyostelium discoideum.
    Huber RJ; O'Day DH
    Cell Mol Life Sci; 2012 Dec; 69(23):3989-97. PubMed ID: 22782112
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab.
    Campanella C; Mottolese M; Cianciulli A; Torsello A; Merola R; Sperduti I; Melucci E; Conti S; Diodoro MG; Zeuli M; Paoletti G; Cognetti F; Garufi C
    J Transl Med; 2010 Apr; 8():36. PubMed ID: 20398370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.